Biblio

Author Title [ Type

] Year

Filters: Author is Crossman, David K [Clear All Filters]

Journal Article

Singh P, Shah DA, Jouni M, Cejas RB, Crossman DK, Magdy T, Qiu S, Wang X, Zhou L, Sharafeldin N, et al. Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 Report. J Am Heart Assoc. 2023:e029954.

Yan C, Richard MA, Gibson CJ, He J, Bosworth A, Crossman DK, Singh P, Hageman L, Kalra R, Armenian SH, et al. Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma. J Clin Oncol. 2024:JCO2302547.

Jin L, Chen Y, Muzaffar S, Li C, Mier-Aguilar CA, Khan J, Kashyap MP, Liu S, Srivastava R, Deshane JS, et al. Epigenetic switch reshapes epithelial progenitor cell signatures and drives inflammatory pathogenesis in hidradenitis suppurativa. Proc Natl Acad Sci U S A. 2023;120(49):e2315096120.

Singh P, Zhou L, Shah DA, Cejas RB, Crossman DK, Jouni M, Magdy T, Wang X, Sharafeldin N, Hageman L, et al. Identification of novel hypermethylated or hypomethylated CpG sites and genes associated with anthracycline-induced cardiomyopathy. Sci Rep. 2023;13(1):12683.

Kahan SM, Bakshi RK, Ingram JT, R Hendrickson C, Lefkowitz EJ, Crossman DK, Harrington LE, Weaver CT, Zajac AJ. Intrinsic IL-2 production by effector CD8 T cells affects IL-2 signaling and promotes fate decisions, stemness, and protection. Sci Immunol. 2022;7(68):eabl6322.

Shah M, Kumar H, Qiu S, Li H, Harris M, He J, Abraham A, Crossman DK, Paterson A, Welner RS, et al. Low c-Kit expression identifies primitive therapy-resistant CML stem cells. JCI Insight. 2022.

Qiu S, Sheth VS, Yan C, Liu J, Chacko BK, Li H, Crossman DK, Fortmann SD, Aryal S, Rennhack A, et al. Metabolic Adaptation to Tyrosine Kinase Inhibition in Leukemia Stem Cells. Blood. 2023.

Anderson NR, Sheth V, Li H, Harris MW, Qiu S, Crossman DK, Kumar H, Agarwal P, Nagasawa T, Paterson AJ, et al. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling. Leukemia. 2022.